81431154 l

Remedium Bio

We believe that any disease can be cured.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded February 2020
  • Employees 3
  • Incorporation Type C-corp
  • Website remedium-bio.com

Company Summary

Remedium modularly applies proven technologies to treat well characterized disease pathology. Our lead candidate is a first-in-class, gene therapy potentially capable of regenerating cartilage in Osteoarthritis ($38B global market, 9% CAGR). Using a well-characterized delivery vector, Remedium aims to reprogram the cells of the joint to produce the only clinically proven molecule to increase cartilage thickness in controlled, randomized trials.


  • Alex
    Chief Operating Officer

    15+ years experience in biotech and gene therapy at companies ranging from start-up to Fortune 500 (Allergan, Biogen, Regeneron, Avedro / Glaukos, and Anika). Experience developing and launching blockbuster products including Enbrel and Humira biosimilars, Spinraza, Praluent, Kevzara, Cingal, among numerous others.

  • 224fd37e 1cc6 4064 b8a9 f3989e6fe98a
    President and CEO

    20+ years biotech and rheumatology experience, brought multiple blockbuster products to market including Monovisc, Orthovisc, Cingal, and Hyalofast (several of which are currently distributed by JNJ). Grew previous company as COO from a cap of $6M to $1B.

  • E117a613 d818 473d 8279 3ac60b60fbfb
    Vice President of R&D

    Dr. Seregin is a subject matter expert in gene therapy and virology with an extensive background leading R&D organizations at companies including Biogen, Takeda, Bioverativ, and Solid Biosciences.